Clinical Trials Directory

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb? (LXS) Oral Powder in Patients With Recurrent or Resistant Neuroblastoma

RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide LXS in treating patients with recurrent, refractory, or persistent neuroblastoma.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : ketoconazole
  • drug : fenretinide lipid matrix
  • other : pharmacological study
  • other : laboratory biomarker analysis

Phase: Phase 1

Eligibility

Ages Eligible For Study:

N/A - 30 Years

External Links

Explore related trials

Contact information

Primary Contact:

Judy Hallagan 6507248811

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: